Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired blood disorder characterized by hemolytic anemia, thrombosis, and impaired bone marrow function. Given its spectrum of disease, PNH is associated with significant disease burden. Importantly, there have been ongoing advances related to current and emerging therapeutic options for its management that offer significant promise.
This online, on-demand virtual symposium features a panel discussion among hematology experts, highlighting the implications and applications of data regarding the treatment and management of PNH. The panel discusses topics that include the efficacy and safety of available and investigational therapies, strategies for treatment planning, and quality of life aspects for affected patients.
This educational activity is an archive of the live virtual symposium held on January 28, 2021.